NextCure Posts Virtual Event Replay on SIM0505 Phase 1 Efficacy and FDA Fast-Track
NXTC•NextCure has posted a replay of its virtual KOL event reviewing first clinical efficacy results from its Phase 1 dose-escalation study of SIM0505, an anti-CDH6 ADC with TOPOi payload, in ovarian cancer and uterine serous carcinoma. SIM0505 has received FDA Fast Track designation for platinum-resistant ovarian cancer.
1. Virtual KOL Event Replay
NextCure has made its virtual key opinion leader event replay available, featuring expert discussions from leading oncologists and scientists on SIM0505 clinical results presented at ASCO 2026.
2. Phase 1 Dose-Escalation Data
The event highlighted first reported efficacy outcomes from an open-label Phase 1 dose-escalation study of SIM0505 in ovarian cancer and uterine serous carcinoma, including preliminary anti-tumor activity and safety observations.
3. FDA Fast Track Designation
SIM0505 has been granted Fast Track designation by the FDA for platinum-resistant ovarian cancer, aimed at accelerating its clinical development and potential review timeline.
4. SIM0505 Mechanism and Rights
SIM0505 is an antibody-drug conjugate targeting Cadherin-6 with a topoisomerase 1 inhibitor payload designed for broad anti-tumor activity and rapid clearance; NextCure retains exclusive global rights outside Greater China.
